Alpha 2.0
Login Register
» Authors » J B Mesic

J B Mesic

Explore the profile of J B Mesic including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 372
Followers 0
Related Specialties
Oncology
Radiology
Top 10 Co-Authors
M V Pilepich
G E Hanks
C A Lawton
D Grignon
C T Coughlin
W U Shipley
K Winter
M Machtay
R L Doggett
W Sause
Published In
Int J Radiat Oncol Biol Phys
J Clin Oncol
Gynecol Oncol
Am J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610
Pollack A, Grignon D, Heydon K, Hammond E, Lawton C, Mesic J, et al.
J Clin Oncol . 2003 Mar; 21(7):1238-48. PMID: 12663710
Purpose: DNA ploidy has consistently been found to be a correlate of prostate cancer patient outcome. However, a minority of studies have used pretreatment diagnostic material and have involved radiotherapy...
2.
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
Pilepich M, Winter K, John M, Mesic J, Sause W, Rubin P, et al.
Int J Radiat Oncol Biol Phys . 2001 Aug; 50(5):1243-52. PMID: 11483335
Purpose: To test the hypothesis that androgen ablation before and during radiotherapy for locally advanced carcinoma of the prostate may, by reducing tumor bulk and enhancing tumor cell kill, improve...
3.
Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
Lawton C, Winter K, Murray K, Machtay M, Mesic J, Hanks G, et al.
Int J Radiat Oncol Biol Phys . 2001 Mar; 49(4):937-46. PMID: 11240234
Purpose: To determine the potential advantage of androgen ablation following standard external-beam radiation therapy in patients with locally advanced (clinical or pathologic T3; clinical or pathologic node positive) carcinoma of...
4.
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31
Pilepich M, Caplan R, Byhardt R, Lawton C, Gallagher M, Mesic J, et al.
J Clin Oncol . 1997 Mar; 15(3):1013-21. PMID: 9060541
Purpose: Although androgen suppression results in a tumor response/remission in the majority of patients with carcinoma of the prostate, its potential value as an adjuvant has not been substantiated. Materials...
5.
Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva
Russell A, Mesic J, Scudder S, Rosenberg P, Smith L, Kinney W, et al.
Gynecol Oncol . 1992 Oct; 47(1):14-20. PMID: 1427394
Between July 1987 and September 1991 a program of external beam radiation and synchronous, radiopotentiating chemotherapy was employed to treat 25 women with locoregionally advanced or locoregionally recurrent squamous cancer...
6.
The value of radiation therapy as an adjuvant to surgery in intracranial meningiomas
Mesic J, Hanks G, Doggett R
Am J Clin Oncol . 1986 Aug; 9(4):337-40. PMID: 3751972
Our experience with benign and malignant intracranial meningiomas between 1970 and 1983 is reported. Fourteen cases were treated after surgery, 10 benign and four malignant, following complete or incomplete resection...
7.
Megavoltage irradiation of epithelial tumors of the nasopharynx
Mesic J, FLETCHER G, Goepfert H
Int J Radiat Oncol Biol Phys . 1981 Apr; 7(4):447-53. PMID: 6788731
No abstract available.